# CheckMate 205 (NCT02181738)

> Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus doxorubicin plus vinblastine plus dacarbazine
- Indication: classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02181738
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Hodgkin Disease
- Interventions: Nivolumab; Doxorubicin; Vinblastine; Dacarbazine
- Enrollment: 294
- Primary outcome: Objective Response Rate (ORR) Based on IRRC Assessments in Cohorts A, B, and C
- Primary outcome: Number of Participants Who Experienced at Least One Treatment Related Grade 3-5 AE in Cohort D

## Indexed commentary on CheckMate 205 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-205-nct02181738

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02181738", "email": "<work email>"}; the inbox owner confirms by the emailed link.